RIPE Knowledge Graph
RIPE-KG · Version 1.1.0 · Resource

ripekg:work/10.1002%2Fptr.6406

https://w3id.org/ripe/ripe-kg/work/10.1002%2Fptr.6406
SubjectPredicateObject
ripekg:publication-details/RIPEA3A616563C128D80EHesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial ripe:concerns ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial
ripekg:registry-evidence/RIPEA3A616563C128D80E ripe:concerns ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial
ripekg:research-integrity-assessment/RIPEA3A616563C128D80E ripe:assesses ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial
ripekg:study-design-evidence/RIPEA3A616563C128D80E ripe:concerns ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial prism:doi 10.1002/ptr.6406
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAU0CCDC4D2825E55BCMehdi Hedayati
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAU394336D804AC0E45Azita Hekmatdoost
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAU54170F81C15D3113Shahrzad Ommi
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAUA390A0CF0C25818AElahe Karimi‐shahrbabak
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAUAB1B8AC88843C93EHossein Imani
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAUB19B1C05A842DE6EZahra Yari
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAUBFF480868D53E342Makan Cheraghpour
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:creator ripekg:author/RIPEAUC71CBB547B5CBAC3Seyed Alavian
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial dcterms:title Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fhep.20701Design and validation of a histological scoring system for nonalcoholic fatty liver disease
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fhep.23276Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1002%2Fptr.5881Hesperidin supplementation alleviates oxidative DNA damage and lipid peroxidation in type 2 diabetes: A randomized double-blind placebo-controlled clinical trial
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1007%2Fbf00280883Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.biocel.2005.12.002Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.jhep.2004.09.012The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.jhep.2005.11.030Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.jhep.2010.05.037Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fj.nutres.2014.09.005Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1016%2Fs0002-9440%2810%2963489-xOxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1038%2Fnm1201-1291Possible new role for NF-κB in the resolution of inflammation
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1046%2Fj.1462-8902.2001.00038.xAttenuating CV risk factors in patients with diabetes: Clinical evidence to clinical practice
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1053%2Fj.gastro.2006.05.054Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1056%2Fnejmoa0907929Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1080%2F07315724.2014.891269Hesperidin supplementation modulates inflammatory responses following myocardial infarction
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1093%2Fjn%2F129.6.1182Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: Cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1097%2F00041433-200212000-00016
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fj.1572-0241.1999.01377.xNonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1111%2Fliv.13299The epidemiology of non-alcoholic fatty liver disease
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1139%2Fcjpp-2014-0204Hesperidin protects against cyclophosphamideinduced hepatotoxicity by upregulation of PPARγ and abrogation of oxidative stress and inflammation
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1186%2F1476-511x-10-36Citrus flavonoids repress the mRNA for stearoyl-CoA desaturase, a key enzyme in lipid synthesis and obesity control, in rat primary hepatocytes
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1210%2Fjc.2010-2879Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.1371%2Fjournal.pone.0195502The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat dietinduced obesity
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.3109%2F09637486.2016.1161011Flaxseed supplementation in non-alcoholic fatty liver disease: A pilot randomized, open labeled, controlled study
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.3748%2Fwjg.v22.i44.9674Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.3945%2Fajcn.113.068890Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.3945%2Fan.116.013151Nonalcoholic fatty liver disease, the gut microbiome, and diet
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.3945%2Fjn.110.124735The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/10.4254%2Fwjh.v7.i25.2597Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW2B6163F26F6A0551Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: An acceptable alternative for liver biopsy
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW5CA9FC45BB3B4E52Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: Is the combination required?
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW641C3AD2EA386B96Role of acyl-CoA: Cholesterol acyltransferase in cellular cholesterol metabolism
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW68FA6BABF4DE7120Ginger supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW734AC08890280B31Antidiabetic effects of hesperidin and naringin in type 2 diabetic rats
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW78FD615F6B477302Effect of plant flavonoids on mammalian cells: Implications for inflammation, heart diseases and cancer
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEW7CE47321C21E606FAssessment of physical activity of adolescents in Isfahan
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEWADA0D17D37EC22B5The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: A pilot study
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEWBD6FCAB6719FD368Non alcoholic fatty liver: Epidemiology and natural history
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEWD3FFD629FB34F261and North American Association for the Study of Obesity. 2000. The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEWE35133B37FDC28A6Hesperidin inhibits insulin-induced phosphoinositide 3-kinase/Akt activation in human pre-B cell line NALM-6
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial http://purl.org/spar/cito/cites ripekg:work/RIPEWF6A55594DD556652Diagnosis and evaluation of nonalcoholic fatty liver disease
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type node1
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type http://purl.org/spar/fabio/Work
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type rdfs:Resource
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type owl:Thing
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type prov:Entity
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial rdf:type ripe:WorkWork
ripekg:work/10.1002%2Fptr.6406Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo‐controlled, double‐blind clinical trial owl:sameAs https://semopenalex.org/work/W2953846051